Logo

Shelford Group responds to new medicines and technologies consultation

The Shelford Group has responded to the National Institute for Health and Care Excellence (NICE) and NHS England consultation on ‘Proposals for changes to the arrangements for evaluating and funding drugs and other health technologies appraised through NICE’s technology appraisal and highly specialised technologies programme’.
by Shelfor
17 Jan 2017

The Shelford Group has responded to the National Institute for Health and Care Excellence (NICE) and NHS England consultation on ‘Proposals for changes to the arrangements for evaluating and funding drugs and other health technologies appraised through NICE’s technology appraisal and highly specialised technologies programme’.

It has been widely recognised that there is a growing gap between the costs of healthcare, driven by our ageing population and scientific advances, and the public funding available. The NHS needs to strike a difficult balance between meeting patients’ expectations for access to new medicines and technologies of proven value and efficacy, and the need to balance budgets within constrained resources. It is important that there should continue to be consistency nationally on how this balance is achieved.

The proposals outlined in the consultation document from NICE and NHS England potentially offer a pragmatic way forward to managing new funding pressures associated with high-cost medicines and technologies from now until the end of the decade. We identify two essential requirements that need further development: transparency of costs and engagement with patients and providers. This will allow the proposals to work most effectively to meet patients’ needs, reduce new cost pressures and ensure providers are properly reimbursed.

However, these arrangements should be temporary until UK economic growth allows the Government to return NHS spending levels closer to the historical trend. This will be important to ensure that the NHS is able to give patients timely access to new medicines and technologies and that the UK can remain a globally attractive partner for biomedical researchers and the life sciences industry.

The full submission can be found here

Share this Article

← House of Lords Long Term Sustainability → Shelford Group submit evidence to Brexit and Health and Social Care inquiry
© 2017 — The Shelford Group
Login

Keep up to date

Follow The Shelford Group on Twitter and our RSS Feed.

If you would like more information about the Shelford Group or to get in touch, please click here